Cephalon aims Nuvigil at depression

Cephalon won't let Provigil go gently into that post-patent night. Already, the drugmaker has readied its follow-up: Nuvigil, an extended release form of the stay-awake drug. Like Effexor and Effexor XR before it (and Wellbutrin and Wellbutrin SR and Wellbutrin XL, and any number of other follow-up twin/triplets), Nuvigil is designed to capture market share from Provigil with its simpler dosing regimen.

And Nuvigil is like those antidepressants in another respect: Cephalon is testing it as--yes--an antidepressant. And today, Cephalon announced some favorable data from a Phase II trial: As an add on to mood-stabilizers for major depression in adults with bipolar disorder, Nuvigil improved depressive symptoms as measured by a common inventory. "We are encouraged that the results of this study point toward the potential utility of NUVIGIL in managing the depressive episodes in bipolar I disorder," said Dr. Lesley Russell, Cephalon's EVP and chief medial officer.

Next comes Phase III trials in bipolar patients. And if Nuvigil performs, that would open up a huge new market for the drug. As the company's press release notes, some 2 million adults suffer from the psychiatric disorder. That's huge, especially compared with the sleep apnea-sufferer/narcoleptic/shift-worker population now covered by Provigil and Nuvigil's FDA approvals.

Meanwhile, Cephalon is prepping for its Nuvigil launch, planned for the third quarter of 2009--and shareholders chuffed by the new trial results for Nuvigil are bidding up Cephalon stock. Shares jumped by 6.6 percent to $67.38 in midday trading.

- read the Cephalon release
- check out the stock story from the AP

Suggested Articles

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.

Hengrui's Sun Piaoyang is stepping down as chairman, but he'll retain control of the pharma major he's headed for 30 years—and made a fortune…

Astellas tapped Adaptimmune to develop T-cell therapies. Ireland hit Takeda with an unexpected Shire tax bill. PD-1 med Tyvyt hit its goal in NSCLC.